These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24262766)

  • 21. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia.
    Kishi T; Iwata N
    Int J Neuropsychopharmacol; 2014 Feb; 17(2):343-54. PubMed ID: 23823741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
    Citrome L
    Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.
    Meeker AS; Herink MC; Haxby DG; Hartung DM
    Syst Rev; 2015 Mar; 4():21. PubMed ID: 25874839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
    Solmi M; Veronese N; Zaninotto L; van der Loos ML; Gao K; Schaffer A; Reis C; Normann C; Anghelescu IG; Correll CU
    CNS Spectr; 2016 Oct; 21(5):403-418. PubMed ID: 27686028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials.
    Kishi T; Matsuda Y; Nakamura H; Iwata N
    J Psychiatr Res; 2013 Feb; 47(2):149-54. PubMed ID: 23131856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review of St. John's wort for major depressive disorder.
    Apaydin EA; Maher AR; Shanman R; Booth MS; Miles JN; Sorbero ME; Hempel S
    Syst Rev; 2016 Sep; 5(1):148. PubMed ID: 27589952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials.
    Oya K; Matsuda Y; Matsunaga S; Kishi T; Iwata N
    Eur Arch Psychiatry Clin Neurosci; 2016 Aug; 266(5):439-50. PubMed ID: 26303414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Oya K; Kishi T; Iwata N
    Hum Psychopharmacol; 2014 Sep; 29(5):483-91. PubMed ID: 25087702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Melatonin receptor agonists-ramelteon and melatonin-for bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials.
    Kishi T; Nomura I; Sakuma K; Kitajima T; Mishima K; Iwata N
    Neuropsychiatr Dis Treat; 2019; 15():1479-1486. PubMed ID: 31239683
    [No Abstract]   [Full Text] [Related]  

  • 33. Intranasal sumatriptan for acute migraine attacks: a systematic review and meta-analysis.
    Menshawy A; Ahmed H; Ismail A; Abushouk AI; Ghanem E; Pallanti R; Negida A
    Neurol Sci; 2018 Jan; 39(1):31-44. PubMed ID: 28942578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: a meta-analysis of double-blind randomized placebo-controlled trials.
    Kishi T; Mukai T; Matsuda Y; Moriwaki M; Iwata N
    J Psychiatr Res; 2013 Nov; 47(11):1557-63. PubMed ID: 23899496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis.
    Galling B; Calsina Ferrer A; Abi Zeid Daou M; Sangroula D; Hagi K; Correll CU
    Expert Opin Drug Saf; 2015 Oct; 14(10):1587-608. PubMed ID: 26360500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
    Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY
    Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drugs versus placebo for dysthymia.
    Lima MS; Moncrieff J
    Cochrane Database Syst Rev; 2000; (4):CD001130. PubMed ID: 11034701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: A comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635.
    de Boer SF; Lesourd M; Mocaer E; Koolhaas JM
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1125-33. PubMed ID: 10027850
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.